New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
04:55 EDTCMRX, CMRX, CMRX, CMRX, CMRX, CMRX, PFE, PFE, PFE, PFE, PFE, PFE, GILD, GILD, GILD, GILD, GILD, GILD, GSK, GSK, GSK, GSK, GSK, GSK, BMY, BMY, BMY, BMY, BMY, BMY, RHHBY, RHHBY, RHHBY, RHHBY, RHHBY, RHHBY, AZN, AZN, AZN, AZN, AZN, AZN, SRPT, SRPT, SRPT, SRPT, SRPT, SRPTInternational Society for Antiviral Research to hold a conference
27th International Conference on Antiviral Research to be held in Raleigh, North Carolina on May 12-17.
News For CMRX;PFE;GILD;GSK;BMY;RHHBY;AZN;SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
January 16, 2015
16:36 EDTRHHBYMarket finishes week lower on continued oil, global growth worries
Subscribe for More Information
14:54 EDTGILDGilead at high of day, up 3% after reaching hep C drug pact with Aetna
14:46 EDTGILDAetna, Gilead confirm discount pricing for hepatitis C drugs Harvoni, Sovaldi
Subscribe for More Information
13:05 EDTGILDGilead granted orphan status for pulmonary arterial hypertension treatment
The FDA granted Gilead orphan status for its treatment of pulmonary arterial hypertension. Reference Link
09:37 EDTGILDActive equity options trading
Subscribe for More Information
08:31 EDTGSKGlaxoSmithKline CEO says more IPOs like ViiV could happen, Retuers says
Subscribe for More Information
06:21 EDTRHHBYRoche acquires Trophos for EUR120M plus contingent payments
Roche has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France. Trophos’s proprietary screening platform generated olesoxime, TRO19622, which is being developed for SMA – a rare and debilitating genetic neuromuscular disease that is most commonly diagnosed in children. Results from a pivotal phase II clinical trial with olesoxime in SMA showed a beneficial effect on the maintenance of neuromuscular function in individuals with Type II and non-ambulatory Type III SMA, as well as a reduction in medical complications associated with the disease. These data were first presented in April 2014 at the annual meeting of the American Academy of Neurology. Under the terms of the agreement, Trophos’s shareholders will receive an upfront cash payment of EUR 120M, plus additional contingent payments of up to EUR 350M based on achievement of certain predetermined milestones.
January 15, 2015
15:26 EDTSRPTSarepta says no safety info or comparison in BioMarin presentation
Sarepta (SRPT) said that, given the small sample size of study 201/202, the company understood the importance of providing an "extensive amount of date" in order to understand eteplirsen's treatment effect. Sarepta has reported mITT data since week 24 and has continued to provide updates on this same mITT at every timepoint, the company said. BioMarin's (BMRN) presentation on Monday focused on extension phase and excluded dose-escalation phase and results during off-treatment periods, according to Sarepta. "Sarepta has regularly reported complete 201/202 safety data on all patients. No safety information or comparison [was included] in BioMarin's Monday presentation," Sarepta wrote in slides for its presentation at the JPMorgan Healthcare Conference.
14:31 EDTGSKMylan launches generic Epivir-HBV tablets
Mylan (MYL) announced the U.S. launch of its Lamivudine Tablets, 100 mg, which is the generic version of GlaxoSmithKline's (GSK) Epivir-HBV. Mylan received final approval from the U.S. FDA for its Abbreviated New Drug Application for this product, which is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation. Lamivudine Tablets, 100 mg, had U.S. sales of approximately $18.1M for the 12 months ending September 30, 2014, according to IMS Health. Currently, Mylan has 284 ANDAs pending FDA approval representing $109.1B in annual brand sales, according to IMS Health. Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $29.3B in annual brand sales, for the 12 months ending June 30, 2014, according to IMS Health.
11:20 EDTPFE, GILDGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
08:36 EDTGSKOncoMed enrolls first biomarker-selected patient in Notch1 antibody Phase trial
Subscribe for More Information
07:59 EDTPFEAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information
07:13 EDTSRPTJPMorgan to hold a conference
Subscribe for More Information
January 14, 2015
10:30 EDTRHHBYHuman Longevity signs genome sequencing pact with Roche unit
Human Longevity announced a multi-year agreement with Genentech, a member of the Roche Group, to conduct whole genome sequencing of tens of thousands of de-identified samples from Genentech. HLI, using proprietary tools and unique expertise, will sequence genomes to 30x coverage and analyze the data. Financial details of the agreement were not disclosed.
09:36 EDTGILDActive equity options trading
Subscribe for More Information
08:30 EDTSRPTSarepta says first patient dosed in European Phase 1/II SRP-4053 study
Subscribe for More Information
07:37 EDTAZNJPMorgan to hold a conference
Subscribe for More Information
07:08 EDTGILDGilead still poised to beat 2015 estimates, says RBC Capital
Subscribe for More Information
07:03 EDTAZNAstraZeneca says Pegasus-TIMI 54 study met primary efficacy endpoint
AstraZeneca announced that the PEGASUS-TIMI 54 study, a large scale outcomes trial involving over 21,000 patients, successfully met its primary efficacy endpoint. The study assessed BRILINTA tablets at either 60mg twice daily or 90mg twice daily plus low-dose aspirin for the secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to study start. The primary efficacy endpoint was a composite of cardiovascular death, myocardial infarction or stroke. Preliminary analysis did not reveal any unexpected safety issues. Full evaluation of the data is ongoing. The PEGASUS-TIMI 54 study investigated two different doses of ticagrelor on a background of low dose aspirin versus placebo plus low dose aspirin, in patients aged 50 and older with a history of heart attack and one additional CV risk factor. The study was designed to better understand the management of patients more than 12 months after their heart attack, who remain at high risk for major thrombotic events. Complete results from the PEGASUS-TIMI 54 study will be submitted to a scientific meeting in 2015 and pending further analysis, AstraZeneca plans to file this data with regulatory health authorities. The PEGASUS-TIMI 54 study is part of AstraZeneca’s PARTHENON program. The PLATO study, involving over 18,000 ACS patients, was the first study in the program and is the basis on which ticagrelor has been approved in over 100 countries and included in 12 major ACS treatment guidelines globally. Further ongoing PARTHENON studies are investigating ticagrelor for the prevention of cardiovascular events in patients with peripheral arterial disease, ischaemic stroke or transient ischaemic attack, and in patients with diabetes and coronary atherosclerosis. BRILINTA is not approved for secondary prevention of atherothrombotic events in patients with a history of heart attack beyond one year or for the prevention of cardiovascular events in patients with PAD, stroke, diabetes or atherosclerosis.
07:03 EDTAZNAstraZeneca says Pegasus-TIMI 54 study met primary efficacy endpoint
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use